Page 245 - 2021_05-Haematologica-web

Letters to the Editor
Identifier: NCT03897036, NCT03904862, NCT00891280, and NCT0357143). Based on our find- ings that MYC, but not CK2, is the key factor for HR-ALL maintenance, it is important to simultaneously target MYC and CK2. Although directly targeting MYC remains challenging, combination treatment of CX4945 with inhibitors targeting MYC-regulated oncogenic pathways, such as metabolism and stress response pathways, may be highly effective and beneficial to patients with HR- ALL, and possibly other cancers with high expression of MYC and CK2.
Yun Zhou,1,2* Haiwei Lian,2,3* Ning Shen,2,4
Sovannarith Korm,2 Andrew Kwok Ping Lam,2
Olivia Layton,2 Leah N. Huiting,2 Dun Li,2 Kelly Miao,2 Aozhuo Zeng,2 Esther Landesman-Bollag,4 David C. Seldin,4 Hui Fu,3 Li Hong1 and Hui Feng2,4
1Department of Gynecology, Wuhan University Renmin Hospital, Wuhan, Hubei, P. R. China; 2Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA; 3Department of Anatomy and Embryology, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei, P. R. China and 4Department of Medicine, Section of Hematology and Medical Oncology, Boston University School of Medicine, Boston, MA, USA
*YZ and HL contributed equally as co-first authors. Correspondence: HUI FENG - huifeng@bu.edu HONG LI - drhongli1011@yeah.net doi:10.3324/haematol.2020.246918
Received: January 7, 2020.
Accepted: August 4, 2020.
Pre-published: August 13, 2020.
Disclosures: no conflicts of interest to disclose.
Contributions: HF, DCS, EB, DL, YZ and HWL developed the concepts of this work; YZ, HWL and DL developed the methodology; OL and AL validated the work; YZ, HWL, AL and OL did the for- mal anlysis; YZ, HWL, SK, NS, LNH, AL, OL, KM, AZ, and EB performed the research; HFu, DCS, and EB provided the resources; YZ, HWL, SK, NS, LNH, OL and AL analyzed the data; YZ, HWL, L.N.H and H.Feng prepared the initial draft and wrote the manuscript; HFeng, HFu, SK, NS, OL, AL, and LH reviewed and edited the manuscript; HFeng, HFu, and LH supervised the research.
Acknowledgments: we thank Dr. Alejandro Gutierrez for providing us the MYC-ER fish and Dr. David M. Langenau for sharing primer sequences for genes specifically expressed in zebrafish T and B cells.
Funding: H.Feng acknowledges the grant support from the National Institutes of Health (NIH) (CA134743 and CA215059), Boston University (Ralph Edwards Career Development Professorship and 1UL1TR001430 grant from the Clinical & Translational Science Institute), the Leukemia Research Foundation (Young Investigator
Award), the American Cancer Society (RSG-17-204-01-TBG), and the St. Baldrick Foundation (Career Development Scholar Award); YZ and SK are grateful for the International Scholar grant from the Dahod family; HWL acknowledges an International Scholar Grant from the St. Baldrick Foundation; NS and DL received training support through NHLB1 T32 HL7501 from the NIH, H.Fu acknowl- edges NSFC 81371338 grant from the National Science Foundation of China and Wuhan University Intramural Funding. The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
References
1. Ko RH, Ji L, Barnette P, et al. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol. 2010;28(4):648-654.
2. Borga C, Foster CA, Iyer S, et al. Molecularly distinct models of zebrafish Myc-induced B cell leukemia. Leukemia. 2019;33(2):559- 562.
3. Bonaccorso P, La Rosa M, Andriano N, et al. Clinical significance of Ck2 (CSNK2) and C-Myc expression in childhood acute lym- phoblastic leukemia. Blood. 2016;128(22):5269.
4. Borgo C, Ruzzene M. Role of protein kinase CK2 in antitumor drug resistance. J Exp Clin Cancer Res. 2019;38(1):287.
5. Piazza F, Manni S, Ruzzene M, et al. Protein kinase CK2 in hemato- logic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia. 2012;26(6):1174-1179.
6. Piazza F. Protein kinase CK2 in normal and malignant hematopoiesis. In: Pinna LA, editor. Protein Kinase CK2. 2013. Chapter 13:344-362. 7. Chua MM, Ortega CE, Sheikh A, et al. CK2 in cancer: cellular and
biochemical mechanisms and potential therapeutic target.
Pharmaceuticals (Basel). 2017;10(1):18.
8. Gowda C, Sachdev M, Muthusami S, et al. Casein kinase II (CK2) as
a therapeutic target for hematological malignancies. Curr Pharm Des.
2017;23(1):95-107.
9. Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine
lymphoma: relation to theileriosis in cattle. Science. 1995;267(5199):
894-897.
10. Penner CG, Wang Z, Litchfield DW. Expression and localization of
epitope-tagged protein kinase CK2. J Cell Biochem. 1997;64(4):525-
537.
11. Gutierrez A, Grebliunaite R, Feng H, et al. Pten mediates Myc onco-
gene dependence in a conditional zebrafish model of T cell acute
lymphoblastic leukemia. J Exp Med. 2011;208(8):1595-1603.
12. Feng H, Langenau DM, Madge JA, et al. Heat-shock induction of T- cell lymphoma/leukaemia in conditional Cre/lox-regulated trans-
genic zebrafish. Br J Haematol. 2007;138(2):169-175.
13. Borga C, Park G, Foster C, et al. Simultaneous B and T cell acute lym- phoblastic leukemias in zebrafish driven by transgenic MYC: impli- cations for oncogenesis and lymphopoiesis. Leukemia. 2019;
33(2):333-347.
14. Garcia EG, Iyer S, Garcia SP, et al. Cell of origin dictates aggression
and stem cell number in acute lymphoblastic leukemia. Leukemia. 2018;32(8):1860-1865.
haematologica | 2021; 106(5)
1465